Cargando…

Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer

Several alterations in fibroblast growth factor receptor (FGFR) genes have been found in breast cancer; however, they have not been well characterized as therapeutic targets. Futibatinib (TAS-120; Taiho) is a novel, selective, pan-FGFR inhibitor that inhibits FGFR1-4 at nanomolar concentrations. We...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saridogan, Turcin, Akcakanat, Argun, Zhao, Ming, Evans, Kurt W., Yuca, Erkan, Scott, Stephen, Kirby, Bryce P., Zheng, Xiaofeng, Ha, Min Jin, Chen, Huiqin, Ng, Patrick K. S., DiPeri, Timothy P., Mills, Gordon B., Rodon Ahnert, Jordi, Damodaran, Senthil, Meric-Bernstam, Funda
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657448/ https://www.ncbi.nlm.nih.gov/pubmed/37980453 http://dx.doi.org/10.1038/s41598-023-46586-y

Ejemplares similares

Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors
por: Javle, Milind, et al.
Publicado: (2023)

Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study
por: Meric-Bernstam, Funda, et al.
Publicado: (2022)

Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1–4 inhibitor in patients with advanced solid tumors
por: Bahleda, R., et al.
Publicado: (2020)

Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan
por: Zhao, Ming, et al.
Publicado: (2023)

Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss
por: Owusu-Brackett, Nicci, et al.
Publicado: (2020)

Targeting translation initiation in breast cancer
por: Akcakanat, Argun, et al.
Publicado: (2014)

Futibatinib: second EMA approval for FGFR inhibitor in cholangiocarcinoma
por: Lamarca, A., et al.
Publicado: (2023)

TAK228 enhances antitumor activity of eribulin in triple negative breast cancer
por: Owusu-Brackett, Nicci, et al.
Publicado: (2019)

The rapamycin-regulated gene expression signature determines prognosis for breast cancer
por: Akcakanat, Argun, et al.
Publicado: (2009)

Preclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric Rhabdomyosarcoma
por: Wu, Jerry T., et al.
Publicado: (2023)

FGFR1β is a driver isoform of FGFR1 alternative splicing in breast cancer cells
por: Zhao, Ming, et al.
Publicado: (2019)

Correction: FGFR1β is a driver isoform of FGFR1 alternative splicing in breast cancer cells
por: Zhao, Ming, et al.
Publicado: (2019)

Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer
por: Arango, Natalia Paez, et al.
Publicado: (2017)

Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer
por: Meric-Bernstam, Funda, et al.
Publicado: (2012)

First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models
por: Pairawan, Seyed, et al.
Publicado: (2021)

Epithelial to mesenchymal transition is associated with rapamycin resistance
por: Holder, Ashley M., et al.
Publicado: (2015)

Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer
por: Evans, Kurt W., et al.
Publicado: (2021)

Phase I study of the irreversible fibroblast growth factor receptor 1–4 inhibitor futibatinib in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2022)

Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations
por: Pairawan, Seyed, et al.
Publicado: (2022)

Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers
por: DiPeri, Timothy P., et al.
Publicado: (2023)

Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors
por: Hassan, Burhan, et al.
Publicado: (2014)

Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer
por: Woo, S-U, et al.
Publicado: (2017)

Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic Cholangiocarcinoma
por: DiPeri, Timothy P., et al.
Publicado: (2022)

Clinical Outcomes of Patients with Recurrent Microsatellite-Stable Endometrial Cancer in Early-Phase Immunotherapy Clinical Trials
por: How, Jeffrey A., et al.
Publicado: (2022)

Whole Genome Sequencing in Cancer Clinics
por: Chen, Ken, et al.
Publicado: (2014)

Personalized cancer therapy—leveraging a knowledge base for clinical decision-making
por: Dumbrava, Ecaterina Ileana, et al.
Publicado: (2018)

A phase I, open‐label, single‐dose study to evaluate the effect of hepatic impairment on the pharmacokinetics and safety of futibatinib
por: Gao, Ling, et al.
Publicado: (2023)

Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes
por: McAuliffe, Priscilla F., et al.
Publicado: (2015)

Correction: Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes
por: McAuliffe, Priscilla F., et al.
Publicado: (2016)

Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors
por: Wheler, Jennifer J., et al.
Publicado: (2016)

Inhibition of autophagy potentiates the cytotoxicity of the irreversible FGFR1-4 inhibitor FIIN-2 on lung adenocarcinoma
por: Jia, Xiuqin, et al.
Publicado: (2022)

Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibition
por: Coleman, Niamh, et al.
Publicado: (2021)

Total neoadjuvant therapy for locally advanced gastric cancer: too much of a good thing?
por: DiPeri, Timothy P., et al.
Publicado: (2023)

Somatic mutations, clinicopathologic characteristics, and survival in patients with untreated breast cancer with bone-only and non-bone sites of first metastasis
por: Kono, Miho, et al.
Publicado: (2018)

Prevalence of actionable mutations and copy number alterations and the price of a genomic testing panel
por: Shen, Chan, et al.
Publicado: (2016)

Efficacy of Quality Criteria to Identify Potentially Harmful Information: A Cross-sectional Survey of Complementary and Alternative Medicine Web Sites
por: Walji, Muhammad, et al.
Publicado: (2004)

Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma
por: Habra, Mouhammed Amir, et al.
Publicado: (2019)

Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences
por: Yao, Shuyang, et al.
Publicado: (2022)

T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy
por: Stephen, Bettzy, et al.
Publicado: (2023)

Reconstructing mutational lineages in breast cancer by multi-patient-targeted single-cell DNA sequencing
por: Leighton, Jake, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vogej37dg6s1a63ov9a09ascb7